Osteoporosis is a chronic disease in which the bone density and bone mass is reduced to such an extent that the bones and cartilages become more prone to cracks and fractures.

A new research report published by Transparency Market Research states that the global osteoporosis drugs market will grow due to increasing prevalence of osteoporosis. The report, titled “Osteoporosis Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends & Forecast 2014 - 2020”, is compiled with accurate information regarding the market. The industry experts have used SWOT analysis and Porter’s five forces analysis to analyze the key trends and dynamics likely to impact this market.

Download Free Report Brochure For Details Study:http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=133
The global osteoporosis market is segmented on the basis of drug class and geography. On the basis of drug class, the global osteoporosis market is segmented into bisphosphonates, parathyroid hormone therapy (PTH) drugs, selective estrogen receptor modulators (SERMs), RANK ligand inhibitors, calcitonin, and other such as others Vitamin D and calcium. This segment also includes drugs that are in the pipeline. Geographically, this market is segmented into Europe, North America, Asia Pacific, and Rest of the World.

Out of the drug class segments, bisphosphonates were the fastest growing segment and held 48.2% of the overall osteoporosis drugs market in 2013. However, analysts predict that pipeline drugs will showcase accelerated growth at a CAGR of 125.20% from 2014 to 2020.The International Osteoporosis Foundation (IOF) stated that at least 9 mn fractures and bone cracks occur every year. In addition to this, about 200 mn women across the world are expected to be victims of osteoporosis with each passing year. With these alarming figures, growth of the global osteoporosis drug is only expected to accelerate. In addition, introduction of new drug classes that hold the promise of overcoming the threat of chronic and generics side effects of the established drugs is yet another factor making a positive influence on the growth of the global osteoporosis drugs market.

In terms of geography, North America holds a major share in the global osteoporosis drugs market. This can be credited to the presence of a huge pool of patients suffering from osteoporosis, growing awareness about the disease, technological advancements and adoption of the same, and presence of state-of-the-art medical infrastructure. However, the research report predicts that Asia Pacific will be the next region to create a huge wave of demand in the osteoporosis drugs market from 2014 to 2020.

Some of the important players in the global osteoporosis drugs market are Novartis International AG, Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc., and Amgen, Inc., Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Actavis plc, and Novo Nordisk A/S. The report opens a discussion about the competitive landscape of the global osteoporosis drugs market and states details pertaining to company overview, financial overview, research and development activities, business and marketing strategies, and lists the existing products and those in the pipeline.

Browse Full Report:http://www.transparencymarketresearch.com/osteoporosis-drug-market.html

The global osteoporosis drugs market is segmented on the basis of:

Osteoporosis Drugs Market, by Drug Class
Bisphosphonates
Parathyroid Hormone Therapy (PTH) Drugs
Selective Estrogen Receptor Modulators (SERMs)
RANK Ligand Inhibitors
Calcitonin
Others (Vitamin D, Calcium)
Pipeline Analysis

Article Tags: Global Osteoporosis Drugs, Osteoporosis Drugs Market, Global Osteoporosis, Osteoporosis Drugs, Drugs Market, Increasing Prevalence, Drug Class